Mad Money w/ Jim Cramer Mad Money w/ Jim Cramer 1/13/25
Jan 14, 2025
Discover how Venue is reshaping the live music scene and what that means for investors. Unpack the effects of government restrictions on semiconductor and pharmaceutical innovations, featuring insights on NVIDIA and Bristol-Myers. Dive into groundbreaking treatments for schizophrenia, including the promising drug Cobenphi. Explore the rise of Boston Scientific at a key healthcare conference, and learn about cutting-edge medical technologies tackling stroke prevention. Finally, analyze the fluctuating landscape of quantum computing stocks and the perils of speculative investments.
AI Snips
Chapters
Transcript
Episode notes
Zuckerberg's Apple Criticism
- Mark Zuckerberg criticized Apple for stifling innovation and taxing app developers.
- Jim Cramer viewed these comments as self-serving, considering Apple's high customer satisfaction.
Impact of Inflation Reduction Act
- The government targeting drug prices under the Inflation Reduction Act disincentivizes risky R&D.
- Without profits from essential medicines like Eliquis, companies like Bristol-Myers can't invest in tackling intractable diseases.
Cobenphy for Schizophrenia
- Bristol-Myers Squibb's new schizophrenia drug, Cobenphy, has fewer side effects than existing treatments.
- It improves patients' positive symptoms and cognition, enabling re-engagement with families.